Premium
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators
Author(s) -
Heppt Markus V.,
Leiter Ulrike,
Steeb Theresa,
Amaral Teresa,
Bauer Andrea,
Becker Jürgen C.,
Breitbart Eckhard,
Breuninger Helmut,
Diepgen Thomas,
Dirschka Thomas,
Eigentler Thomas,
Flaig Michael,
Follmann Markus,
Fritz Klaus,
Greinert Rüdiger,
Gutzmer Ralf,
Hillen Uwe,
Ihrler Stephan,
John Swen Malte,
Kölbl Oliver,
Kraywinkel Klaus,
Löser Christoph,
Nashan Dorothée,
Noor Seema,
Nothacker Monika,
Pfannenberg Christina,
Salavastru Carmen,
Schmitz Lutz,
Stockfleth Eggert,
Szeimies RolfMarkus,
Ulrich Claas,
Welzel Julia,
Wermker Kai,
Berking Carola,
Garbe Claus
Publication year - 2020
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.14048
Subject(s) - actinic keratosis , guideline , medicine , dermatology , actinic keratoses , psychological intervention , basal cell , keratosis , family medicine , nursing , pathology
Summary Actinic keratoses (AK) are common lesions in light‐skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence‐based framework for clinical decision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” was developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office‐based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, policy makers and insurance funds. In the first part, we will address aspects relating to diagnosis, interventions for AK, care structures and quality‐of‐care indicators.